{
  "docId": "019de510-c0ed-7699-8bf7-892eb75d2a26",
  "docSlug": "43fded91ff08c45a8a96283b7b8b25cc",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 14 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 14,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "business_model",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a split-screen layout to contrast the revenue models for two distinct market segments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de510-c0ed-7699-8bf7-892eb75d2a26/6",
  "deckHref": "/decks/019de510-c0ed-7699-8bf7-892eb75d2a26",
  "deckJsonHref": "/decks/019de510-c0ed-7699-8bf7-892eb75d2a26.json",
  "deckAnchorHref": "/decks/019de510-c0ed-7699-8bf7-892eb75d2a26#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.32,
        "x": 0.34,
        "y": 0.0045
      },
      "kind": "image",
      "text": "STx and GTx instrument photos",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d14202e-5cfc-43f4-b1ad-ed2b9e3331f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.44,
        "x": 0.53,
        "y": 0.32
      },
      "kind": "list",
      "text": "Licenses granted for 140+ cell therapy programs, 100+ for clinical use; > $950m in pre-commercial milestones",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00324067-050f-4aa8-b973-965f4f0557df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.44,
        "x": 0.03,
        "y": 0.32
      },
      "kind": "list",
      "text": "Blue-chip client base includes 20 of the top 25 and all of the top ten global pharma companies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f00f005b-fafb-4ade-8474-4300ca421b7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.44,
        "x": 0.03,
        "y": 1
      },
      "kind": "paragraph",
      "text": "DRUG DISCOVERY & DEVELOPMENT - CELLS TO DISCOVER DRUGS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ed7c434-484d-4e59-a581-764ed0513f86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.44,
        "x": 0.53,
        "y": 1
      },
      "kind": "paragraph",
      "text": "CELL THERAPY - CELLS AS DRUGS",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc9b04f9-b839-43f0-9714-121f54df6302",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "* Top pharma by revenue ** Includes RUO- non-exclusive license only; $129,000 list price for STx sale *** $150,000 per year list price for pre-clinical use or $250,000 per year list price for clinical use",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "813b49fd-b3d6-4373-ba5a-5ca43e11da28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "MaxCyte: Strength in opportunities from two high-value life science markets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "738b32b0-1ca8-4f1d-b023-ae1e79906cdf",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "razor-razor-blade-economics",
      "slug": null,
      "matchId": "d67b0249-bf63-4a1e-8dc2-2a651e4aaa69",
      "evidence": "Explicitly stated in both columns as the revenue model",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 6,
      "from": 6,
      "beatId": "f66a6de7-e8b1-4f65-9361-113ea0d35046",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Business Model",
      "beatSlug": "sequoia-pitch-business-model",
      "evidence": "MaxCyte's business model is described as serving two high-value life science markets",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 6,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "8df65546-5d83-4381-a128-9886e4271ec2",
      "evidence": "The business model slide highlights two high-value life science markets",
      "position": 1,
      "objective": "Growth opportunities",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}